Kura Oncology is a clinical-stage biopharmaceutical company engaged in developing medicines for the treatment of cancer. Co.'s primary product candidate, ziftomenib, is a selective, reversible and oral small molecule inhibitor which blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene. Co.'s second product candidate, tipifarnib, is a selective and orally bioavailable inhibitor of farnesyl transferase. Co. is evaluating tipifarnib in multiple solid tumor and hematologic indications. We show 35 historical shares outstanding datapoints in our KURA shares outstanding history coverage, used to compute KURA market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing KURA market cap history over the course of time is important for investors
interested in comparing KURA's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of KURA versus a peer is one thing; comparing
KURA market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like KURA can fluctuate over the course of history.
With this page we aim to empower investors researching KURA by allowing them to research the KURA market cap history. |
Free KURA Email Alerts:
Video: The Importance of Market Cap
